Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis

NeuroReport

Volumn 14, Issue 14, 2003, Pages 1867-1869

  Johansson, Anders ^a   Larsson, Anders ^a   Nygren, Ingela ^a   Blennow, Kaj ^b   Askmark, Håkan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Amyotrophic lateral sclerosis; bFGF; Cerebrospinal fluid; FGF 2; Serum

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

ADULT; AGE DISTRIBUTION; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; GROWTH REGULATION; HUMAN; HYPOTHESIS; HYPOXIA; IMMUNOASSAY; MALE; MOTONEURON; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MIDDLE AGED;

EID: 0242643654     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200310060-00022     Document Type: Article

References (25)

1. Appel SH. Ann Neurol 10, 499-505 (1981).
2. Sendtner M. Neurotrophic factors. In: Brown RH Jr, Meininger V, Swash M (eds). Amyotrophic Lateral Sclerosis. London: Martin Dunitz; 2000, pp. 289-308.
3. Bikfalvi A, Klein S, Pintucci G and Rifkin DB. Endocrin Rev 18, 26-45 (1997).
4. Alzheimer C and Werner S. Fibroblast growth factors and neuroprotection. In: Alzheimer C (ed.). Molecular and Cellular Biology of Neuroprotection in the CNS. New York: Kluwer Academic; 2002, pp. 335-351.
5. Cordon-Cardo C, Vlodavsky I, Haimovitz-Friedman A et al. Lab Invest 63, 832-840 (1990).
6. Kerkhoff H, Hassan SM, Troost D et al. Acta Neuropathol (Berl) 87, 411-421 (1994).
7. Ortega S, Ittmann M, Tsang SH et al. Proc Natl Acad Sci USA 95, 5672-5677 (1998).
8. Ikeda K, Kinoshita M and Iwasaki Y. Muscle Nerve 19, 794-795 (1996).
9. Oosthuyse B, Moons L, Storkebaum E et al. Nature Genet 28, 131-138 (2001).
10. Nygren I, Larsson A, Johansson A and Askmark H. Neuroreport 13, 2199-2201 (2002).
11. Subcommittee on Motor Neuron Diseases of World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical Limits of Amyotrophic Lateral Sclerosis Workshop Contributors. J Neurol Sci 124, 96-107 (1994).
12. ALS CNTF Treatment Study Phase I-II Study Group. Arch Neurol 53, 141-147 (1996).
13. Gonzalez AM, Berry M, Maher PA et al. Brain Res 701, 201-226 (1995).
14. Goddard DR, Berry M, Kirvell SL and Butt MB. J Anat 200, 57-67 (2002).
15. Aquilonius SM, Jossan SS, Ekblom JG et al. J Neural Transm Gen Sect 89, 111-122 (1992).
16. Ganat Y, Soni S, Chacon M et al. Neuroscience 112, 977-991 (2002).
17. Liu X, Zheng SX, Zhou LJ and Zhu XZ. Acta Pharmacol Sin 21, 19-22 (2000).
18. Yoshimoto T, Houkin K, Takahashi A and Abe H. Stroke 27, 2160-2165 (1996).
19. MacMillan V, Judge D, Wiesman A et al. Stroke 24, 1735-1739 (1993).
20. Upton-Rice MN, Cudkowicz ME, Warren L et al. Ann Neurol 46, 934 (1999).
21. Kruchkova Y, Ben-Dror I, Herschkovitz A et al. J Neurochem 77, 1641-1649 (2001).
22. Borisov AB, Huang SK and Carlson BM. Anat Rec 258, 292-304 (2000).
23. Karpati G, Klassen G and Tanser P. Can J Neurol Sci 6, 105-112 (1979).
24. Kuwabara K, Ogawa S, Matsumoto M et al. Proc Natl Acad Sci USA 92, 4606-4610 (1995).
25. Rohovsky S, Kearney M, Pieczek A et al. Am Heart J 132, 1015-1019 (1996).